山河药辅(300452) - 2023 Q3 - 季度财报

Financial Performance - Revenue for Q3 2023 reached ¥187,411,687.03, an increase of 13.43% year-over-year, and cumulative revenue for the year-to-date was ¥640,355,017.44, up 21.93% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was ¥35,201,835.29, representing a 23.65% increase year-over-year, with year-to-date net profit at ¥123,531,091.50, up 30.54%[4] - Basic and diluted earnings per share for Q3 2023 were both ¥0.15, reflecting a 25.00% increase compared to the same quarter last year[4] - The net profit for Q3 2023 was CNY 125,689,496.75, an increase of 34.4% compared to CNY 93,461,300.05 in Q3 2022[25] - Operating profit reached CNY 141,682,634.11, up from CNY 105,348,970.98, reflecting a growth of 34.5% year-over-year[25] - The total comprehensive income for the period was CNY 125,689,496.75, compared to CNY 93,461,300.05 in the previous year, indicating a growth of 34.4%[26] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥1,482,423,518.34, a 25.57% increase from the end of the previous year[4] - As of September 30, 2023, total assets reached CNY 1,482,423,518.34, an increase from CNY 1,180,550,962.11 at the beginning of the year, representing a growth of approximately 25.6%[22] - The company's total liabilities as of September 30, 2023, amounted to CNY 582,139,890.22, compared to CNY 391,933,246.05 at the beginning of the year, marking an increase of about 48.5%[22] - Total current assets increased to CNY 880,185,319.57 from CNY 631,320,405.29, reflecting a growth of approximately 39.3%[21] - The company’s non-current assets totaled CNY 602,238,198.77, up from CNY 549,230,556.82, representing an increase of approximately 9.7%[22] Cash Flow - The cash flow from operating activities showed a decline of 17.30% year-to-date, totaling ¥47,218,824.42[4] - Cash flow from operating activities generated CNY 47,218,824.42, down from CNY 57,097,827.18 in the same period last year[28] - Net cash flow from investment activities for the year-to-date was -317.1869 million yuan, a decrease of 654.64% year-on-year, primarily due to increased cash payments for purchasing financial products and fixed asset construction[11] - Net cash flow from financing activities for the year-to-date was 236.9416 million yuan, an increase of 510.81% year-on-year, mainly due to funds raised from convertible bonds[11] - The cash and cash equivalents at the end of the period were CNY 89,701,241.43, compared to CNY 83,437,409.98 at the end of Q3 2022[28] - The company’s cash and cash equivalents decreased to CNY 116,515,129.94 from CNY 150,119,055.59, a reduction of about 22.4%[20] Investments and Construction - The company reported a significant increase in trading financial assets, which rose by 131.03% to ¥495,710,100.00, primarily due to the purchase of financial products[7] - The company’s investment income decreased by 35.02% year-to-date, totaling ¥3,862,200.00, mainly due to reduced returns from matured financial products[9] - The company is continuing the construction of a new pharmaceutical auxiliary production base, which has led to a 44.00% increase in construction in progress, totaling ¥222,607,700.00[7] - The new pharmaceutical excipient production base project has entered the trial production phase as of September 2023, indicating progress in market expansion efforts[18] - The company reported a significant increase in investment activities, with cash outflow for investments reaching CNY 678,312,000.00, compared to CNY 318,750,000.00 in the previous year[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,855[12] - The largest shareholder, Yin Zhenglong, holds 26.89% of shares, totaling 63,057,454 shares[13] - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. holds 11.20% of shares, totaling 26,254,059 shares[13] - The top ten shareholders include various natural persons and investment funds, with the smallest holding being 0.59%[14] - The company has a total of 48,095,265 restricted shares, with 62,400 shares released during the period[17] - The company has implemented a three-phase release plan for restricted shares, starting 12 months after the completion of the grant registration[17] Research and Development - Research and development expenses increased to CNY 30,674,826.71, a rise of 27.5% from CNY 24,076,821.87 in the previous year[25] - In Q3 2023, the company launched 3 new products registered with CDE, enhancing its high-end product development capabilities[18] Miscellaneous - The company did not undergo an audit for the Q3 report[30] - The impact of exchange rate fluctuations on cash for the year-to-date was 22,200 yuan, a decrease of 98.88% year-on-year, primarily due to reduced foreign exchange gains from currency fluctuations[11] - Minority shareholder profit for the year-to-date reached 2.1584 million yuan, an increase of 285.07% year-on-year, mainly due to reduced losses from the controlling company Qufu Tianli[11] - The company’s inventory decreased to CNY 73,642,045.66 from CNY 91,197,744.75, a decline of approximately 19.2%[21]